Upfront liquid next-generation sequencing in treatment-naïve advanced non-small cell lung cancer patients: A prospective randomised study in the Taiwanese health system

•Liquid NGS finds treatable mutations in over 60% of East Asian NSCLC patients.•Upfront liquid NGS shortens the time to treatment by 8 days in advanced NSCLC.•Liquid NGS detects 42.6% of cases missed by four-gene tissue testing.